Literature DB >> 21448361

Hyperthermic intraperitoneal chemotherapy for gastric and colorectal cancer in Mainland China.

Tao Suo1, Haile Mahteme, Xin-Yu Qin.   

Abstract

AIM: To investigate the current status of peritoneal carcinomatosis (PC) management, as well as the usage of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in mainland China.
METHODS: A potentially curative therapeutic strategy for selecting patients with PC, known as "Techniques", consists of CRS in combination with HIPEC. A systemic search of published works and clinical trials was performed. Additional papers were retrieved by cross-checking references and obtaining information from Chinese oncologists and relevant conferences. One hundred and one papers and one registered clinical trial on HIPEC were included.
RESULTS: A literature review identified 86 hospitals in 25 out of all 31 areas of mainland China that perform HIPEC. The earliest report included in our survey was published in 1993. Different approaches to HIPEC have been utilized, i.e. palliative, prophylactic, and possibly curative treatment. Only one center has consistently performed HIPEC according to the "Sugarbaker Protocol", which involves evaluating the extent of PC with peritoneal cancer index and the results of CRS with the completeness of cytoreduction. Positive preliminary results were reported: 7 of 21 patients with PC survived, free of tumors, during an 8-43-mo follow-up period. Hyperthermic strategies that include HIPEC have been practiced for a long time in mainland China, whereas the "Sugarbaker Protocol/Techniques" has been only rarely implemented in China. The Peritoneal Surface Oncology Group International hosts a biannual workshop with the intent to train more specialists in this field and provide support for the construction of quality treatment centers, especially in developing countries like China, whose population is huge and has a dramatically increased incidence of cancer.
CONCLUSION: To popularize Sugarbaker Protocol/Techniques in mainland China in PC management arising from gastric cancer or colorectal cancer will be the responsibility of the upcoming Chinese Peritoneal Surface Oncology Group.

Entities:  

Keywords:  Hyperthermia; Mainland China; Peritoneal carcinomatosis; Prophylactic strategy; Sugarbaker Protocol/techniques

Mesh:

Substances:

Year:  2011        PMID: 21448361      PMCID: PMC3057152          DOI: 10.3748/wjg.v17.i8.1071

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  [Early postoperative intraperitoneal perfusion chemotherapy for advanced colorectal cancer].

Authors:  N Sun; Z Cai; C Zhang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  1998-05

2.  [Curative effect of radical gastrectomy combined with peritoneal lavage with thermal hypoosmotic solution in treatment of gastric cancer].

Authors:  J Chen; S Wang; H Xu
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2001-06-25

3.  Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors.

Authors:  D Z Chu; N P Lang; C Thompson; P K Osteen; K C Westbrook
Journal:  Cancer       Date:  1989-01-15       Impact factor: 6.860

4.  Identification and classification of serosal invasion, as it relates to cancer cell shedding and surgical treatment in gastric cancer.

Authors:  J Chen; Q Liu
Journal:  Semin Surg Oncol       Date:  1994 Mar-Apr

5.  Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.

Authors:  Qing-Guo Fu; Fan-Dong Meng; Xiao-Dong Shen; Ren-Xuan Guo
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

6.  [Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer].

Authors:  Guo Wei; Guo-En Fang; Jian-Wei Bi; Xiao-Jun Shen; Ming-Ming Nie; Xu-Chao Xue; Ji-De Hua
Journal:  Ai Zheng       Date:  2005-04

7.  Cancer trends in China.

Authors:  Ping Zhao; Min Dai; Wanqing Chen; Ni Li
Journal:  Jpn J Clin Oncol       Date:  2010-01-18       Impact factor: 3.019

Review 8.  Natural history of peritoneal carcinomatosis from nongynecologic malignancies.

Authors:  Olivier Glehen; Dimitri Osinsky; Annie Claude Beaujard; François Noël Gilly
Journal:  Surg Oncol Clin N Am       Date:  2003-07       Impact factor: 3.495

Review 9.  Technology of hyperthermic intraperitoneal chemotherapy in the United States, Europe, China, Japan, and Korea.

Authors:  Jesus Esquivel
Journal:  Cancer J       Date:  2009 May-Jun       Impact factor: 3.360

Review 10.  Management of peritoneal carcinomatosis from colorectal cancer: current state of practice.

Authors:  Eddy Cotte; Guillaume Passot; Faheez Mohamed; Delphine Vaudoyer; François Noël Gilly; Olivier Glehen
Journal:  Cancer J       Date:  2009 May-Jun       Impact factor: 3.360

View more
  3 in total

1.  Upregulated Heat Shock Proteins After Hyperthermic Chemotherapy Point to Induced Cell Survival Mechanisms in Affected Tumor Cells From Peritoneal Carcinomatosis.

Authors:  Tanja Grimmig; Eva-Maria Moll; Kerstin Kloos; Rebecca Thumm; Romana Moench; Simone Callies; Jennifer Kreckel; Malte Vetterlein; Joerg Pelz; Buelent Polat; Sudipta Tripathi; Roberta Rehder; Carmen M Ribas; Anil Chandraker; Christoph-T Germer; Ana Maria Waaga-Gasser; Martin Gasser
Journal:  Cancer Growth Metastasis       Date:  2017-09-18

2.  Inhibitory effect and mechanism of exogenous mammalian sterile 20-like kinase 1 on the growth of human colorectal cancer.

Authors:  Jian Wu; Xiaohong Yang; Hongfei Lu; Liqiao Liu; Baohua Xu; Shuangyan Zheng; Bo Yu; Kemin Jie; Fusheng Wan
Journal:  Oncol Lett       Date:  2017-02-28       Impact factor: 2.967

3.  Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy: a multidisciplinary study of peritoneal carcinomatosis.

Authors:  Maciej Nowacki; Marek Wisniewski; Karolina Werengowska-Ciecwierz; Katarzyna Roszek; Joanna Czarnecka; I Łakomska; Tomasz Kloskowski; Dominik Tyloch; Robert Debski; Katarzyna Pietkun; Marta Pokrywczynska; Dariusz Grzanka; Rafał Czajkowski; Gerard Drewa; A Jundziłł; Joseph K Agyin; Samy L Habib; Artur P Terzyk; Tomasz Drewa
Journal:  Oncotarget       Date:  2015-09-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.